FDA D.I.S.C.O. Burst Edition: FDA approval of Polivy (polatuzumab vedotin-piiq) for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma
0:00
3:30
Listen to a soundcast of the April 19, 2023, FDA approval of Polivy (polatuzumab vedotin-piiq) for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma.
Weitere Episoden von „FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)“
Verpasse keine Episode von “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” und abonniere ihn in der kostenlosen GetPodcast App.